key: cord-0687298-gv59x2wj
authors: Tsitsiklis, A.; Zha, B. S.; Byrne, A.; Devoe, C.; Levan, S.; Rackaityte, E.; Sunshine, S.; Mick, E.; Ghale, R.; Jauregui, A.; Sarma, A.; Neff, N.; Serpa, P. H.; Deiss, T. J.; Kistler, A.; Carrillo, S.; Ansel, K. M.; Leligdowicz, A.; Christenson, S.; Jones, N.; Wu, B.; Darmanis, S.; Matthay, M. M.; Lynch, S. V.; DeRisi, J. L.; COMET Consortium,; Hendrickson, C. M.; Kangelaris, K. N.; Krummel, M. F.; Woodruff, P. G.; Earle, D. J.; Rosenberg, O.; Calfee, C. S.; Langelier, C. R.
title: Impaired antibacterial immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19
date: 2021-03-26
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2021.03.23.21253487
sha: 8e821db9460343c26c513cd7de84a3881d68aeba
doc_id: 687298
cord_uid: gv59x2wj

Secondary bacterial infections, including ventilator associated pneumonia (VAP), lead to worse clinical outcomes and increased mortality following viral respiratory infections. Critically ill patients with coronavirus disease 2019 (COVID-19) face an elevated risk of VAP, although susceptibility varies widely. Because mechanisms underlying VAP predisposition remained unknown, we assessed lower respiratory tract host immune responses and microbiome dynamics in 36 patients, including 28 COVID-19 patients, 15 of whom developed VAP, and eight critically ill controls. We employed a combination of tracheal aspirate bulk and single cell RNA sequencing (scRNA-seq). Two days before VAP onset, a lower respiratory transcriptional signature of bacterial infection was observed, characterized by increased expression of neutrophil degranulation, toll-like receptor and cytokine signaling pathways. When assessed at an earlier time point following endotracheal intubation, more than two weeks prior to VAP onset, we observed a striking early impairment in antibacterial innate and adaptive immune signaling that markedly differed from COVID-19 patients who did not develop VAP. scRNA-seq further demonstrated suppressed immune signaling across monocytes/macrophages, neutrophils and T cells. While viral load did not differ at an early post-intubation timepoint, impaired SARS-CoV-2 clearance and persistent interferon signaling characterized the patients who later developed VAP. Longitudinal metatranscriptomic analysis revealed disruption of lung microbiome community composition in patients who developed VAP, providing a connection between dysregulated immune signaling and outgrowth of opportunistic pathogens. Together, these findings demonstrate that COVID-19 patients who develop VAP have impaired antibacterial immune defense weeks before secondary infection onset.

Secondary bacterial pneumonia results in significant morbidity and mortality in patients 74 additionally evaluated eight intubated patients with non-pneumonia illnesses as controls at the 125 "early" time-point. There were no significant differences between groups with respect to age, 126 gender, race or ethnicity (Table S1, S2 ). In addition, there were no differences between groups 127 with respect to in-hospital receipt of any immunosuppressant or antibiotics prior to sample 128 collection (Table S3) . 129 130 COVID-19 VAP is associated with a transcriptional signature of bacterial infection two days 131 before VAP onset 132

We began by assessing the lower respiratory host transcriptional response two days 133 preceding VAP onset in COVID-19 patients. Differential gene expression analysis was carried out 134 on TA bulk RNA-seq data from five patients who developed VAP (samples collected a median of 135 two days before VAP onset) and eight patients who did not develop VAP collected within a similar 136 time frame after intubation (Table S1) hours preceding VAP onset, we next asked whether differences in host immune signaling might 149 exist even earlier, two or more weeks before clinical diagnosis of VAP, and whether such 150 differences might explain the increased susceptibility to secondary bacterial infection in these 151 patients. We thus compared TA gene expression soon after the time of intubation between 152 patients who eventually developed VAP (samples collected a median of two days post-intubation, 153 17 days before VAP onset, n= 4) and patients who did not develop VAP (samples collected a 154 median of two days after intubation, n = 8) ( Table 1) . We identified 154 differentially expressed 155 genes at FDR <0.1. The COVID-19 patients who developed VAP had lower expression of several 156 genes with roles in innate immunity including IFI30, MMP2, TLR9, and DEFB124 ( Figure 3A) . 157 GSEA further revealed that patients who developed VAP had lower expression of pathways 158 related to antibacterial immune responses including neutrophil degranulation, toll-like receptor 159 signaling, IL-17 signaling, antigen presentation and complement pathways and higher expression 160 of IFN-alpha/beta signaling pathways, more than two weeks before the onset of VAP ( Figure 3B ). 161

Additionally, pathways related to adaptive immunity such as T and B cell receptor signaling were 162 also downregulated in patients who subsequently developed VAP ( Figure 3B) . 163

To gauge the degree of immune signaling suppression compared to controls, we 164 performed a similar analysis on critically ill intubated patients without infection ( Figure 3C) . 165

Relative to the control group, multiple antibacterial immune pathways were downregulated in 166 COVID-19 patients, with the greatest attenuation in the VAP group ( Figure 3C ). Upstream 167 regulator analysis identified impaired activation of diverse cytokines in those with VAP, while 168 IFNB1 was notably upregulated ( Figure 3D ). Several pro-inflammatory cytokines were 169 downregulated in both groups compared to the controls ( Figure S1 ). We expanded the 170 comparison at the "early" time-point to include patients with culture-negative VAP (VAP: n=6, No-171 VAP: n=11) and observed similar differences at the pathway level ( Figure S2) . 172

Given prior reports demonstrating correlation between SARS-CoV-2 viral load and 173 interferon related gene expression(14) we next asked whether viral load differed between VAP 174

and No-VAP patients. No differences in SARS-CoV-2 qPCR or viral reads per million (rpM) in bulk 175 RNA-seq data were found in the days following intubation (P = 0.84 (RNA-seq), P = 0.53 (PCR), 176 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure S3 ). We also considered the possibility that differences in the number of days of steroid 177 exposure prior to sample collection might explain results, but found no differences (P = 0.343) 178 (Table S1) . 179 180 COVID-19 VAP is associated with impaired anti-bacterial immune signaling in monocytes, 181 macrophages and neutrophils 182

To further understand the mechanism of early downregulation of key pathways involved 183 in antibacterial responses, we next asked whether this was driven by any one local immune cell 184 type. We performed scRNA-seq on TA specimens obtained early during disease course (median 185 of nine days before VAP) and enriched for immune cells using CD45 selection (Methods). With respect to mono/macs and neutrophils, we identified 532 and 693 differential expressed 194 genes, respectively, at FDR< 0.05. Several genes with key roles in innate immunity were 195 downregulated in both cell types in the COVID-19 patients who subsequently developed VAP 196 versus those who did not, including IL1Rn, ICAM1, NFKB2, and ITGAX in neutrophils, as well as 197 the neutrophil chemokines CXCL2 and CXCL8 in mono/macs ( Figure 4C, 4F, S5 ). In addition, 198 similar to the bulk RNA-seq results demonstrating upregulation of type I IFN signaling at this time-199 point in patients who developed VAP, we noted upregulation of several interferon-induced genes 200 including IFI27 and IFI30 in mono/macs, and IFI30, IFITM1, and IFITM3 in neutrophils ( Figure  201 4C, F). 202 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. IPA canonical pathway analysis of gene expression within each cluster revealed  203   downregulation of several cytokine and innate immune signaling pathways in the patients who  204 later developed VAP at the "early" post-intubation time-point. In the mono/mac cluster, this 205 included downregulation of IL-1, IL-6, and iNOS signaling, as well as Th17 and TNFR2 signaling 206 ( Figure 4D) . Analysis of the neutrophil cluster also demonstrated attenuated IL-1, IL-6, and 207 TNFR2 signaling and NF-κB pathways ( Figure 4G We next investigated temporal dynamics of the lower airway host inflammatory response 227 in COVID-19 patients from the time of intubation to development of VAP by evaluating differential 228 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 5A ). GSEA revealed that type I interferon signaling was notably 233 downregulated at the "late" time-point most immediately preceding VAP onset in comparison to 234 the "early" timepoint ( Figure 5B) ; however, expression was still significantly higher than in the 235

No-VAP patients ( Figure 2B ). Several other immune signaling pathways were more highly 236 expressed at this "late" time-point, presumably reflecting activation of an antibacterial response 237 in the setting of bacterial pneumonia ( Figure 5B ). Consistent with this, upstream regulator 238 analysis indicated increased activation of several pro-inflammatory cytokines and decreased 239 IFN and IFN- signaling at the "late" versus "early" time-points ( Figure 5C ). 240

In contrast, comparing No-VAP patients at the "early" (n=8) versus "late" (n=8) time-points 241 yielded only two genes with a padj <0.1, both of which were interferon-stimulated genes (RSAD2 242 and CMPK2) downregulated at the "late" time-point, suggesting that while the host response was 243 relatively unchanged in these patients, the antiviral response attenuated over time. Indeed, GSEA 244 revealed that type I interferon signaling, and other antiviral immune pathways were downregulated 245 in the patients who did not develop VAP at the later time-point ( Figure S7 ). 246

Next, we performed a similar comparison between the "early" and "late" time-points based 247 

We hypothesized that the innate immune suppression in patients who developed VAP 272 would correlate with viral load. Using TA metatranscriptomics to assess the lower respiratory 273 microbiome, we evaluated longitudinal changes in SARS-CoV-2 abundance. Although no 274 difference was observed at the "early" timepoint ( Figure S3 ), the trajectory of SARS-CoV-2 viral 275 load differed significantly in patients who developed VAP (p=0.0058), although in both groups 276 decreased over time ( Figure 6A ). This result suggested that COVID-19 patients who develop 277 VAP may exhibit impaired ability to clear virus compared to those who do not, and that the lung 278 microbiome composition may be similarly impacted. 279 Indeed, COVID-19 patients who developed VAP exhibited a significant reduction in 280 bacterial diversity of their airway microbiome up to three weeks before clinical signs of infection 281 (Shannon Diversity Index, p=0.012; Figure 6B ). COVID-19 patients who developed VAP also had 282 lower airway microbiome compositions more closely resembling each other than those from 283 patients who did not develop VAP, across all timepoints since intubation (Bray Curtis index, 284 p=0.0033; Figure 6C ), suggesting community collapse precedes the development of VAP. All 285 patients received antibiotics prior to collection of the first sample, suggesting that antibiotic use 286 was not driving these differences (Table S1) . Two days before VAP onset, a transcriptional signature consistent with bacterial infection 298 was observed. This finding suggests that host response changes can occur before clinical 299 recognition of pneumonia, highlighting the potential utility of the host transcriptome as a tool for 300 VAP surveillance. While intriguing, this observation did not provide an explanation for differential 301 susceptibility of some COVID-19 patients to post-viral pneumonia. 302

The discovery of an early suppressed antibacterial immune response in patients who later 303 developed VAP did however, offer a potential explanation. More than two weeks before VAP 304 onset, we observed a striking suppression of pathways related to both innate and adaptive 305 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21253487 doi: medRxiv preprint immunity, including neutrophil degranulation, TLR signaling, complement activation, antigen 306 presentation, and T cell receptor and B receptor signaling, as well as cytokine signaling (e.g. IL -307 1, IL-4, IL-12, IL-13 and IL-17). Comparison against uninfected, intubated controls confirmed the 308 previously described paradoxical impairment in immune signaling found in patients with severe 309 COVID-19(18), and suggested that VAP susceptibility may be the result of disproportionate 310 suppression of innate and adaptive pathways critical for antibacterial defense, resulting in 311 enhanced susceptibility to opportunistic secondary infections. 312

Animal models of influenza have provided insight into potential mechanisms of post-viral 313 pneumonia, although none have provided insight regarding why some individuals are more 314 susceptible than others. In mice inoculated with influenza, for instance, virus-induced type I IFN 315

suppresses neutrophil chemokines and impairs Th17 immunity, compromising effective clearance 316 of bacterial infections(9, 10). Interestingly, we also observed increased type I interferon signaling 317 in COVID-19 patients who weeks later developed VAP, and a strikingly similar impairment in Th17 318 signaling and other immune pathways. Desensitization to toll-like receptor (TLR) ligands after 319 influenza infection has also been documented(20), which is congruent with the downregulation of 320 TLR signaling at the time of intubation observed in our bulk RNA-seq analyses. 321 Impaired bacterial clearance by alveolar macrophages was found to be driven by virus-322 related IFN production by T cells(21) in a murine post-influenza model. In contrast, we found that 323 T cells from patients who later developed VAP expressed lower levels of IFN at the time of 324 intubation. This difference may relate to species-specific variations in immune signaling or intrinsic 325 differences in the host response to influenza virus versus SARS-CoV-2(14, 18). 326

We asked whether certain cell types were responsible for driving the early suppression of 327 immune signaling observed in COVID-19 patients who went on to develop VAP. No significant 328 differences in proportions of the most abundant cell types -monocytes/macrophages, neutrophils 329 or T cellswas observed between patients with or without VAP at the time of intubation. This 330 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. finding suggests that an impairment of immune cell recruitment was not causing these differences, 331 but rather significant gene expression differences within each of these immune cell populations. This observation was corroborated by a prolonged antiviral type I interferon response at the "late" 352 timepoint (median of two days before VAP onset) in patients who developed VAP versus those 353 who did not, pointing to the persistence of suboptimal antiviral immunity in these patients. Early 354 induction of functional SARS-CoV-2 specific T cells is associated with faster viral clearance in 355 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Thus, our results emphasize the need for ongoing vigilance for VAP in patients treated with potent 378 immunosuppressive agents, as well as the need to develop novel diagnostic and/or prognostic 379 approaches to identifying patients at highest risk. For instance, availability of molecular 380 biomarkers to assess a patient's risk of VAP at the time of intubation could reduce inappropriate 381 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. and 20-30497, respectively, which granted a waiver of initial consent for tracheal aspirate and 405 blood sampling. Informed consent was subsequently obtained from patients or their surrogates 406 for continued study participation, as previously described(11). Tracheal aspirate (TA) was 407 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21253487 doi: medRxiv preprint collected and processed for either bulk RNA-seq or scRNA-seq as described below. Of the 408 COVID-19 patients, 19 were co-enrolled in the National Institute of Allergy and Infectious 409

Diseases-funded Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) Network 410 study. IMPACC is a multicenter study that employs a systems biology approach to identify host 411 immunologic and viral determinants of COVID-19 pathophysiology and disease severity. Following enrollment, tracheal aspirate (TA) was collected (periodically following 432 intubation for Study 1, or once within 3 days of intubation for Study 2), without addition of saline 433 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Genes were retained for differential expression analysis if they had counts in at least 30% 457 of samples. Differential expression analysis was performed using the R package DESeq2(31). 458

We modeled the expression of individual genes using the design formula ~VAPgroup, where VAP 459 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21253487 doi: medRxiv preprint groups were "VAP-early", "No VAP-early", "VAP-late" and "No VAP-late" and used the results() 460 function to extract a specific contrast. Separate comparisons to the control group were performed 461 using the design formula ~COVID-19-status to compare positive and negative patients. 462

Significant genes were identified using a Benjamini-Hochberg false discovery rate (FDR) 463 < 0.1. We generated heatmaps of the top 50 differentially expressed genes by FDR. For 464 visualization, gene expression was normalized using the regularized log transformation, centered, 465 and scaled prior to clustering. Heatmaps were generated using the pheatmap package. Columns 466 were clustered using Euclidean distance and rows were clustered using Pearson correlation. 467

Differential expression analysis results are provided in (Supplementary data file 1) . data files 2 and 3) . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Raw sequencing reads were aligned to GRCh38 using the STAR aligner(35). Cell 505 barcodes were then determined based upon UMI count distribution. Read count matrices were 506 generated through the 10X genomics cellranger pipeline v3.0. Data was processed and analyzed 507 using the Scanpy v1.6(36). Cells that had <200 genes and had greater than 30,000 counts were 508 filtered. Mitochondrial genes were removed and multi-sample integration was performed using 509

Harmony v0.1.4(37). Differential expression was performed using MAST v1.16.0(38). Due to the 510 significantly greater number of differentially expressed genes in scRNA-seq analyses, we used a 511 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21253487 doi: medRxiv preprint more restrictive cutoff of FDR < 0.05 for significant genes. Differential expression analysis results 512 are detailed in (Supplementary data file 4) . 513 514 Pathway analysis 515 Ingenuity Pathway Analysis (IPA) Canonical Pathway and Upstream Regulator 516 Analysis(34) was employed on genes with p<0.05 and ranked by log2foldchange to identify 517 canonical pathways and cytokine regulators. We utilized a more restrictive p value cutoff for 518 scRNA-seq to ensure a similar number of genes were input into IPA. Significant IPA results were 519 defined as those with a Z-score absolute value greater than 2 and an overlap P value < 0.05. The 520 gene sets in figures were selected to reduce redundancy and highlight diverse biological 521 functions. Full GSEA and IPA results are provided in (Supplementary data files 5 and 6) . 522 523 Lung microbiome analysis 524 RNA from tracheal aspirates was sequenced as described above. Respiratory microbiome 525 sequences were quality-filtered, human reads removed, and assembled using open-source 526

IDseq pipeline(39, 40), which performs reference based taxonomic alignment at both the 527 nucleotide and amino acid level against sequences in the National Center for Biotechnology 528 Information (NCBI) nucleotide (NT) and non-redundant (NR) databases, followed by assembly of 529 the reads matching each taxon detected. Taxonomic alignments underwent background 530 correction for environmental contaminants (see below), viruses were excluded, and data was then 531 aggregated to the genus level before calculating diversity metrics. Alpha diversity (Shannon's 532 Diversity Index) and beta diversity (Bray-Curtis dissimilarity) were calculated and the latter plotted 533 using non-metric multidimensional scaling (NDMS). Comparison of alpha and beta diversity over 534 time between VAP and No-VAP groups was calculated using a two-way analysis of variance 535 (ANOVA) in GraphPad PRISM. 536 537 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

To minimize inaccurate taxonomic assignments due to environmental and reagent derived 539 contaminants, non-templated "water only" and HeLa cell RNA controls were processed with each 540 group of samples that underwent nucleic acid extraction. These were included, as well as positive 541

control clinical samples, with each sequencing run. Negative control samples enabled estimation 542 of the number of background reads expected for each taxon. A previously developed negative 543 binomial model(14) was employed to identify taxa with NT sequencing alignments present at an 544 abundance significantly greater compared to negative water controls. This was done by modeling 545 the number of background reads as a negative binomial distribution, with mean and dispersion 546 fitted on the negative controls. For each batch (sequencing run) and taxon, we estimated the 547 mean parameter of the negative binomial by averaging the read counts across all negative 548 controls, slightly regularizing this estimate by including the global average (across all batches) as 549 an additional sample. We estimated a single dispersion parameter across all taxa and batches, 550 using the functions glm.nb() and theta.md() from the R package MASS(41). Taxa that achieved a 551 p-value <0.01 were carried forward. 552 553 554 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table S1 : Clinical and demographic data for patients in bulk RNA-seq analyses. 577 Table S2 : Clinical and demographic data for patients in single cell RNA-seq analyses. 578 Table S3 : Details of immunosuppressant use for all patients. 579 580 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Excluded from primary analysis: -N=5 meeting CDC-VAP criteria but with negative cultures (2' analysis) -N=24 with bacterial PNA but not meeting CDC VAP criteria (excluded) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. patients who developed VAP (yellow) versus those who did not (red) at the "late" time-point, 2 817 days before the onset of VAP, from bulk RNA-seq. B) Gene set enrichment analysis (GSEA) at 818 the "late" time-point based on differential gene expression analyses. GSEA results were 819 considered significant with an adjusted P-value <0.05. C) Ingenuity Pathway Analysis (IPA) of 820 upstream cytokines at the "late" time-point based on differential gene expression analyses. IPA 821 results were considered significant with a Z-score absolute value >2 and overlap P-value <0.05. 822 *Denotes cytokines with an overlap P-value < 0. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21253487 doi: medRxiv preprint 858 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21253487 doi: medRxiv preprint 881 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Individual immune responses to SARS-CoV-2 infection drive a restructuring of the microbial 921 community and increase susceptibility to VAP. Those predisposed to VAP have increased type I 922 interferon responses and dysregulated antibacterial immune signaling characterized by impaired 923 macrophage, neutrophil and T cell activity, decreased TLR signaling and impaired activation of 924 key cytokines important for pathogen defense including IL-1, IL-6, IL-8, TNF, and IL-17. This state 925 of suppressed immunity disrupts the lower respiratory tract microbiome, predisposing to 926 outgrowth of bacterial pathogens and VAP. 927 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21253487 doi: medRxiv preprint

Bacterial Complications of Respiratory Tract 604 Viral Illness: A Comprehensive Evaluation

Predominant role of bacterial pneumonia as a 607 cause of death in pandemic influenza: implications for pandemic influenza preparedness

CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a 616 European multicenter cohort study

Ventilator-associated pneumonia in patients with 620 SARS-CoV-2-associated acute respiratory distress syndrome requiring ECMO: a retrospective 621 cohort study

Nosocomial infections associated 624 to COVID-19 in the intensive care unit: clinical characteristics and outcome

Ventilator-associated pneumonia in critically ill patients 630 with COVID-19

Community-acquired and hospital-acquired 634 respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 635 pneumonia

Immune Dysfunction and Bacterial Co-Infections following Influenza

Type I IFNs mediate development of postinfluenza bacterial pneumonia in 640 mice

Influenza A inhibits Th17-mediated 643 host defense against bacterial pneumonia in mice

Integrating host response and unbiased microbe 648 detection for lower respiratory tract infection diagnosis in critically ill adults

Loss of bacterial diversity during 652 antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa

Ventilator-associated [VAP] and non-ventilator-associated 655 Pneumonia

Upper airway gene expression reveals suppressed immune responses to SARS-661

CoV-2 compared with other respiratory viruses

CXCR6 regulates localization of tissue-resident memory CD8 T cells to the airways

Antigen-668 Induced but Not Innate Memory CD8 T Cells Express NKG2D and Are Recruited to the Lung 669 Parenchyma upon Viral Infection

T cell activation

COVID-676 19 ARDS is characterized by a dysregulated host response that differs from cytokine storm and 677 is modified by dexamethasone

Imbalanced host response to SARS-CoV-2 drives development of 679 COVID-19

Sustained desensitization to bacterial Toll-like 682 receptor ligands after resolution of respiratory influenza infection

Inhibition of pulmonary antibacterial defense by interferon-gamma 685 during recovery from influenza infection

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral 689 clearance and mild disease in COVID-19 patients

Lowering the 691 Threshold of Lung Innate Immune Cell Activation Alters Susceptibility to Secondary Bacterial 692 Superinfection

The microbiota of the respiratory 694 tract: gatekeeper to respiratory health

Rhinovirus Infection Induces 698 Degradation of Antimicrobial Peptides and Secondary Bacterial Infection in Chronic Obstructive 699 Pulmonary Disease

702 Outgrowth of the Bacterial Airway Microbiome after Rhinovirus Exacerbation of Chronic 703 Obstructive Pulmonary Disease

Cell-surface 707 signatures of immune dysfunction risk-stratify critically ill patients: INFECT study

Evaluation of the External RNA Controls Consortium (ERCC) 711 reference material using a modified Latin square design

Near-optimal probabilistic RNA-seq 713 quantification

Differential analyses for RNA-seq: transcript-level 715 estimates improve gene-level inferences

Moderated estimation of fold change and dispersion for 717 RNA-seq data with DESeq2

Fast gene set enrichment analysis, bioRxiv

The 723 Reactome pathway knowledgebase

Causal analysis approaches in Ingenuity 725 Pathway Analysis

STAR: ultrafast universal RNA-seq aligner

SCANPY : large-scale single-cell gene expression data 729 analysis

Fast, sensitive, and accurate integration of single cell data with Harmony

MAST: a flexible statistical framework 735 for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA 736 sequencing data

Metagenomic next-generation sequencing of samples 740 from pediatric febrile illness in Tororo

IDseq-An open source cloud-based pipeline and 745 analysis service for metagenomic pathogen detection and monitoring

Modern Applied Statistics with S

We gratefully appreciate support from Amy Kistler

Funding for enrollment of COMET participants not 762 enrolled in IMPACC

01A1 (CL), K24HL137013 (PGW), F32 HL151117 (AS), R35 HL140026 (CSC), and the Chan

Philanthropic support was provided from Mark and Carrie Casey

Martin 766 and Leesa Romo, Three Sisters Foundation

Author contributions: 769 Conceptualization

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 788 789 790 Figure 1: Sample selection and study flowchart

Cohort 1 consisted of COVID-19 patients from the COVID 792 Multiphenotyping for Effective Therapies (COMET) and related Immunophenotyping Assessment 793 in a COVID-19 Cohort (IMPACC) studies (described in Methods)

For 796 COVID-19 patients who developed VAP, the "late" samples were obtained a median of two days 797 before VAP onset. Timing of sample collection with respect to VAP versus No-VAP groups was 798 matched at "early" and "late" time points. Controls included eight critically ill, mechanically 799 ventilated patients without LRTI. All COVID-19 patients included in the primary bulk analysis were 800 also included in the longitudinal host expression and microbiome analyses. Abbreviations: 801 VAP=ventilator-associated pneumonia; TA=tracheal aspirate; QC=quality control; sc or scRNA-802 seq= single cell RNA sequencing; PNA=pneumonia

Acknowledgements: This study was performed with support from the National Institute of Allergy

A) Heatmap of the top 50 differentially expressed genes by adjusted P-value between COVID-19 883 patients who developed VAP at the "early" time-point (blue) versus the "late" time-point (yellow) 884 from bulk RNA-seq. B) Gene set enrichment analysis (GSEA) based on differential gene 885 expression of VAP patients at the "early" vs "late" time-point from bulk RNA-seq. GSEA results 886were considered significant with an adjusted P-value <0.05. C) Ingenuity Pathway Analysis (IPA) 887 of upstream cytokines based on differential gene expression analyses of VAP patients at the 888 "early" vs "late" time-point from bulk RNA-seq. IPA results were considered significant with a Z-889 score absolute value >2 and overlap P-value <0.05. interval were averaged so that each patient corresponds to one datapoint at each interval. 900Samples from day 21+ after intubation are not shown due to a lack of these later time-points in 901the No-VAP group. VAP onset in these patients ranged from 10-39 days post intubation. Selected 902 pathways are innate immune system (F), neutrophil degranulation (G), cytokine signaling (H), and 903adaptive immune system (I). Box plots represent the median and range. Statistical significance 904 was determined by two-way ANOVA, and interaction p-values are shown. 905